JP2015526394A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526394A5
JP2015526394A5 JP2015518522A JP2015518522A JP2015526394A5 JP 2015526394 A5 JP2015526394 A5 JP 2015526394A5 JP 2015518522 A JP2015518522 A JP 2015518522A JP 2015518522 A JP2015518522 A JP 2015518522A JP 2015526394 A5 JP2015526394 A5 JP 2015526394A5
Authority
JP
Japan
Prior art keywords
triazolo
methyl
thieno
pyrimidin
methoxybenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526394A (ja
JP6240180B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/046403 external-priority patent/WO2013192225A1/en
Publication of JP2015526394A publication Critical patent/JP2015526394A/ja
Publication of JP2015526394A5 publication Critical patent/JP2015526394A5/ja
Application granted granted Critical
Publication of JP6240180B2 publication Critical patent/JP6240180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518522A 2012-06-18 2013-06-18 置換チオフェン−およびフラン−縮合アゾロピリミジン−5−(6h)−オン化合物 Active JP6240180B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
PCT/US2013/046403 WO2013192225A1 (en) 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Publications (3)

Publication Number Publication Date
JP2015526394A JP2015526394A (ja) 2015-09-10
JP2015526394A5 true JP2015526394A5 (https=) 2016-07-21
JP6240180B2 JP6240180B2 (ja) 2017-11-29

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518522A Active JP6240180B2 (ja) 2012-06-18 2013-06-18 置換チオフェン−およびフラン−縮合アゾロピリミジン−5−(6h)−オン化合物
JP2015518523A Active JP6129960B2 (ja) 2012-06-18 2013-06-18 置換ピリジンアゾロピリミジン−5−(6h)−オン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015518523A Active JP6129960B2 (ja) 2012-06-18 2013-06-18 置換ピリジンアゾロピリミジン−5−(6h)−オン化合物

Country Status (17)

Country Link
US (7) US9499562B2 (https=)
EP (3) EP2861603B1 (https=)
JP (2) JP6240180B2 (https=)
KR (2) KR102191816B1 (https=)
CN (2) CN104583213B (https=)
AU (3) AU2013277294C1 (https=)
BR (2) BR112014031730B1 (https=)
CA (2) CA2877146C (https=)
DK (2) DK2861603T3 (https=)
ES (2) ES2904267T3 (https=)
IL (2) IL236232A (https=)
IN (2) IN2015DN00335A (https=)
MX (2) MX357320B (https=)
NZ (2) NZ703949A (https=)
RU (2) RU2653054C2 (https=)
SG (3) SG11201408395WA (https=)
WO (2) WO2013192229A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526020T1 (de) * 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training
MX357320B (es) 2012-06-18 2018-07-04 Dart Neuroscience Cayman Ltd Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida.
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
TWI609870B (zh) * 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
RU2019109039A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Pde2阻害剤としての置換ピラゾロピリミジノン化合物
US11066419B2 (en) * 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
EP3585392A1 (en) * 2017-02-23 2020-01-01 Boehringer Ingelheim International GmbH New medical use of compound iii
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
TW201920188A (zh) * 2017-08-10 2019-06-01 美商美國禮來大藥廠 [1,2,4]三唑衍生物
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
ES3060268T3 (en) 2018-04-13 2026-03-25 Cancer Research Tech Ltd Bcl6 inhibitors
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
JP2022545802A (ja) * 2019-08-22 2022-10-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
AU2020343329C1 (en) 2019-09-03 2026-02-12 Intra-Cellular Therapies, Inc. Methods of treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (en) * 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
AU2024298134A1 (en) * 2023-07-24 2026-02-05 Bpgbio, Inc. Tricyclic ube2k modulators and methods for their use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ− アクチエンゲゼルシヤフト 2−置換−e−融合−〔1,2,4〕トリアゾロ−〔1,5−C〕ピリミジン
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) * 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
ATE526020T1 (de) 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
JP2010527243A (ja) 2007-05-15 2010-08-12 ヘリコン セラピューティクス,インコーポレイテッド 低分子干渉RNA(siRNA)を用いた記憶形成に関わる遺伝子の同定方法
US20100203624A1 (en) 2007-09-26 2010-08-12 Ge Healthcare Bioscience Bioprocess Corp. Three dimensional disposable bioreactor
AU2008335811B2 (en) 2007-12-06 2012-05-17 Intra-Cellular Therapies, Inc. Organic compounds
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのpde1阻害剤
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) * 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
MX357320B (es) 2012-06-18 2018-07-04 Dart Neuroscience Cayman Ltd Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida.

Similar Documents

Publication Publication Date Title
JP2015526394A5 (https=)
RU2015100209A (ru) Замещенные соединения тиофен- и фуран-конденсированного азолопиримидин-5-(6н)-она
WO2023018809A1 (en) Heterocyclic compounds and methods of use
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
JP2015526395A5 (https=)
AU2023221732A1 (en) Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2022232331A1 (en) Heterocyclic compounds and methods of use
EP4705293A1 (en) Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
US20250163064A1 (en) Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins
IL275344B2 (en) 4-azaindole compounds
WO2024076670A2 (en) Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2011516558A5 (https=)
JP2017505327A5 (https=)
JP2019535664A5 (https=)
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
JP2005519086A5 (https=)
JPWO2021076602A5 (https=)
CA2474823A1 (en) Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
CN117835976A (zh) 杂环化合物及使用方法
WO2025217247A1 (en) Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
WO2025230862A1 (en) Macrocyclic amino compounds as modulators of kras and uses therof
RU2019116137A (ru) Пиридо[3,4-d]пиримидиновое производное и его фармацевтически приемлемая соль